In addition to demonstrating the safety and efficacy of a subcutaneously administered single-domain antibody for treating cancer, the current study is the first to provide evidence that a single-domain anti-PD-L1 antibody has similar efficacy as full anti-PD-1 monoclonal antibodies in treating dMMR/MSI-H cancer. Here, PDCD1 is linked to cancer.